Malignant gliomas are extremely aggressive cancers currently lacking effective treatment modalities. Gene therapy represents a promising approach for this disease. A requisite component for improving gene-based therapies of brain cancer includes tumor suppressor genes that exhibit cancer constrained inhibitory activity. Subtraction hybridization identified melanoma differentiation associated gene-7 (mda-7) as a gene associated with melanoma cell growth, differentiation and progression. Ectopic expression of mda-7 by means of a replication-incompetent adenovirus (Ad), Ad.mda-7, induces growth suppression and apoptosis selectively in diverse human cancers, without producing any apparent harmful effect in normal cells. We presently demonstrate that Ad.mda-7 induces growth inhibition and apoptosis in malignant human gliomas expressing both mutant and wild-type p53, and these effects correlate with an elevation in expression of members of the growth arrest and DNA damage (GADD) gene family. In contrast, infection with a recombinant Ad expressing wild-type p53, Ad.wtp53, specifically affects mutant p53 expressing gliomas. When tested in early passage normal and immortal human fetal astrocytes, growth inhibition resulting from infection with Ad.mda-7 or Ad.wtp53 is significantly less than in malignant gliomas and no toxicity is evident in these normal cells. Moreover, infection of gliomas with Ad.mda-7 or treatment with purified GST-MDA-7 protein sensitizes both wild-type and mutant p53 expressing tumor cells to the growth inhibitory and antisurvival effects of ionizing radiation, and this response correlates with increased expression of specific members of the GADD gene family. Since heterogeneity in p53 expression is common in evolving gliomas, the present findings suggest that Ad.mda-7 may, in many instances, prove more beneficial for the genebased therapy of malignant gliomas than administration of wild-type p53. Oncogene (2003 Oncogene ( ) 22, 1164 Oncogene ( -1180 Oncogene ( . doi:10.1038 Keywords: cancer gene therapy; malignant brain tumors; apoptosis; radiosensitization Although Ad-mediated gene transfer for the treatment of malignant brain cancers represents a promising therapeutic approach, further development is necessary to fulfill its potential (Alavi and Eck, 1998; Alemany et al., 1999; Gomez-Navarro et al., 1999; Lang et al., 1999; McCormick, 2001; Lebedeva et al., 2003) . This strategy has been used both in vitro and in vivo in experimental animal models to express the tumor suppressor gene wild-type p53 (wtp53) in the context of human gliomas (Broaddus et al., 1999; Cirielli et al., 1999; Lang et al., 1999; Hong et al., 2000) . These experiments emphasize three major limitations of this approach relative to using this scheme to treat patients with malignant gliomas, which include efficiency of tumor cell transduction, selective growth suppression and apoptosis induction in mutant p53 (mutp53) gliomas, and dose-dependent nonspecific toxic effects (inflammation and necrosis) associated with Ad.wtp53 administration to the brain (Lang et al., 1999; Hong et al., 2000) . The problem of specificity for gliomas containing mutp53 is particularly troublesome, since considerable evidence supports the existence of intratumoral heterogeneity with respect to wtp53 and mutp53 even in tumors classified as mutp53 (von Deimling et al., 1993; Wu et al., 1993; Lang et al., 1994 Lang et al., , 1999 Kyritsis et al., 1996) . Moreover, although Ad.wtp53 is relatively nontoxic to wtp53 gliomas, expression of this gene can sensitize these cells to radiation, raising the possibility of induction of toxicity in normal astrocytes containing elevated levels of Ad-transduced wtp53. One way of preventing this nonspecific wtp53 toxic effect would be to use gene promoters, such as E2F-1 or nestin, which display selective expression in gliomas and glioblastomas (Parr et al., 1997; Kurihara et al., 2000) . Unfortunately, this approach would still be problematic when using wtp53, since this gene might not prove of significant benefit in patients with gliomas having a wtp53 genotype, but it might provide a method of more effectively using the combination of wtp53 and radiation in specific gliomas. Additionally, in vivo animal modeling, including subcutaneous glioma xenografts in nude mice and intracerebral orthotopic glioma brain tumor models in rats, indicates that Ad.wtp53 even in the context of mutp53 glioma cells does not result in a cure, which has been attributed to a failure to infect the entire tumor population (Lang et al., 1999) .
A novel cancer growth-suppressing and apoptosisinducing gene, mda-7 (Jiang et al., 1995) , with broadspectrum cancer-specific antitumor properties has been identified by subtraction hybridization (Jiang et al., 1995 (Jiang et al., , 1996 Su et al., 1998 Su et al., , 2001 Madireddi et al., 2000; Saeki et al., 2000 Saeki et al., , 2002 Huang et al., 2001; Mhashilkar et al., 2001; Lebedeva et al., 2002 Lebedeva et al., , 2003 Pataer et al., 2002; Sarkar et al., 2002a, b; Sauane et al., 2003) . In contrast to its harmful effects on tumor cells, mda-7 does not induce toxicity in normal endothelial, breast, bronchial and mammary epithelial, fibroblast or melanocyte cells (Jiang et al., 1996; Su et al., 1998 Su et al., , 2001 Madireddi et al., 2000; Saeki et al., 2000 Saeki et al., , 2002 Ekmekcioglu et al., 2001; Huang et al., 2001; Mhashilkar et al., 2001; Ellerhorst et al., 2002; Lebedeva et al., 2002a; Sarkar et al., 2002a, b; Sauane et al., 2003) . Based on its profound and selective anticancer activity in vitro and in vivo in animal models, a Phase I clinical trial has been performed using a replication-incompetent Ad to express mda-7, Ad.mda-7 . These studies employed intratumoral injection of Ad.mda-7 in patients with advanced carcinomas, and indicated that mda-7 is safe with mild toxicities and this gene could induce apoptosis in a large percentage of tumor volume. Although the normal function of mda-7 and the mechanism underlying its selective antitumor effects are not currently known, this gene would appear to be particularly valuable for the therapy of malignant gliomas for several reasons. Previous studies demonstrate that mda-7 induces growth suppression and apoptosis in histologically diverse cancer cells containing single or multiple genetic defects, including alterations in p53, p16/INK4a and/or Rb (Jiang et al., 1995 (Jiang et al., , 1996 Su et al., 1998 Su et al., , 2001 Madireddi et al., 2000; Saeki et al., 2000; Huang et al., 2001; Mhashilkar et al., 2001; Lebedeva et al., 2002) . Moreover, Ad.mda-7 is equally effective in inducing apoptosis in breast and lung carcinoma and melanoma cells containing wtp53, mutp53 or which are null for p53 expression (Su et al., 1998; Madireddi et al., 2000; Saeki et al., 2000 Saeki et al., , 2002 Huang et al., 2001; Mhashilkar et al., 2001; Lebedeva et al., 2002; Sarkar et al., 2002b) . In addition, mda-7 is secreted from tumor cells (Huang et al., 2001; Mhashilkar et al., 2001; Lebedeva et al., 2002) and, based on its structure, may function as a cancer restricted apoptosis inducing cytokine, thereby permitting a direct bystander effect on adjacent tumor cells Su et al., 2001; Lebedeva et al., 2002; Pestka et al., 2003; Sarkar et al., 2002; Sauane et al., 2003) . Based on its structure, cytokine-like properties and proposed mode of action, mda-7 has now been classified as IL-24 (Kotenko, 2002; Pestka et al., 2003; Sarkar et al., 2002a; Sauane et al., 2003) .
We have presently evaluated the effect of adenovirusadministered mda-7 and wtp53 on the growth and survival of cultured primary normal human fetal astrocytes (PHFA), telomerase (H-TERT) immortalized normal human fetal astrocytes (PHFA-Im) and malignant gliomas. Mda-7 efficiently induced growth suppression and apoptosis in human gliomas, but not in normal astrocytes, and this effect occurred irrespective of the p53 status of the glioma. Initiation of apoptosis in the gliomas by Ad.mda-7 correlated with an induction of the growth arrest and DNA damage (GADD) genes, specifically GADD34, GADD45a and GADD153. In contrast, wtp53 was very effective in suppressing growth and inducing apoptosis in mutp53 gliomas, but these effects were not apparent in a wtp53 glioma. Induction of GADD34, GADD45a and GADD153 by Ad.wtp53 was only apparent in mutp53 gliomas. Infection of malignant gliomas with Ad.mda-7 or treatment with purified GST-MDA-7 protein sensitized these cells to radiation-induced growth suppression and toxicity. This radiosensitization effect was also independent of the p53 status of the glioma and correlated with an enhanced induction of the GADD family of genes. These results document a differential response of glioma vs normal astrocytes to mda-7 and provide support for the application of mda-7 for the gene-based therapy of human gliomas.
Results
Effect of adenovirus-administered mda-7 and wtp53 on growth and transgene expression in PHFA, PHFA-Im and malignant gliomas
The effect of Ad.mda-7 and Ad.wtp53 on the growth of early-passage (#4) PHFA and PHFA-Im (>25 passages in culture), and wtp53, U87MG, and mutp53, U251MG, U373MG and T98G, human gliomas is shown in Figure 1 . Infection of early-passage normal human fetal astrocytes with either virus resulted in modest growth suppression, without decreasing viability. In the case of H-TERT-immortalized PHFA, PHFA-Im, increased growth suppression was observed vs early-passage PHFA following infection with Ad.mda-7 or Ad.wtp53. In contrast, infection of both wtp53 and mutp53 gliomas with Ad.mda-7 resulted in enhanced growth suppression (Figure 1 ). Although quantitatively more effective in reducing growth than mda-7 in mutp53 gliomas, Ad.wtp53 induced significantly less growth inhibition in U87MG cells than observed following infection with Ad.mda-7 (Figure 1 ).
Experiments were performed to define a potential mechanism underlying the differential effect of mda-7 on the growth of normal astrocytes vs malignant gliomas. Infection of PHFA and PHFA-Im with 100 PFU/cell of Ad.mda-7 resulted in readily detectable mda-7 mRNA 6 h postinfection (hpi), with maximum expression evident by 48 hpi (Figure 2a,b) . In contrast, mda-7 mRNA was detected by 12 hpi in U87MG and U251MG cells with maximum expression by 96 hpi (Figure 2c,d ). As observed in normal astrocytes, 6 hpi with 100 PFU/cell of Ad.mda-7 resulted in mda-7 mRNA in U373MG and T98G cells (Figure 2e ,f). These data document that the differential effect of mda-7 on normal astrocytes vs malignant gliomas is not a consequence of differential expression of the mda-7 transgene in normal cells as compared with their cancerous counterparts. Analysis of coxsackie-adenovirus receptors (CAR), which mediate adenovirus attachment and uptake in cells (Hidaka et al., 1999; Li et al., 1999; Pearson et al., 1999; Fechner et al., 2000) , by FACS analysis indicated the following order relative to numbers of and binding to CAR receptors: T98G>U373MG>U251MG>PHFA>U87MG>PH-FA-Im (Table 1) . Since U87MG cells are inhibited to a greater extent than PHFA or PHFA-Im and expression of mda-7 is observed more rapidly in PHFA and PHFAIm than in U87MG or U251MG cells, a simple relationship between virus uptake, transgene expression and differential growth inhibition is not apparent. This conclusion is further supported by analysis of levels of intracellular and secreted MDA-7 protein in PHFA-Im vs the malignant gliomas (Figure 3) . Infection of PHFAIm and U87MG, U251MG and T98G cells with 100 PFU/cell of Ad.mda-7 resulted in a temporal increase in intracellular and secreted MDA-7 protein. Maximum MDA-7 protein expression, both intracellular and secreted, was apparent in Ad.mda-7-infected PHFA-Im cells. As observed previously, multiple intracellular protein species were detected using MDA-7 specific polyclonal antibodies, and higher molecular weight MDA-7 proteins were found in the supernatant of Ad.mda-7-infected normal astrocytes and gliomas ( Figure 3) . These results imply, as previously observed in other cell types Lebedeva et al., 2002) , that the MDA-7 protein is processed prior to secretion, and this processing could involve changes in the extent of phosphorylation and/or glycosylation of the secreted proteins. Based on these results, it can be concluded that the differential response of normal astrocytes vs the malignant gliomas to mda-7 is not simply a consequence of reduced Ad uptake, intracellular mda-7 transgene expression, or production or secretion of MDA-7 protein by normal astrocytes. Previous studies document that Ad.wtp53 differentially affects gliomas, depending on their p53 genotype (Cirielli et al., 1999; Lang et al., 1999; Hong et al., 2000) . The present study confirms a selective effect of wtp53 on the growth of mutp53 human gliomas (Figure 1 ). Western blotting analysis using a p53 monoclonal antibody, which detects both wtp53 and mutp53, indicates elevated p53 protein in PHFA-Im, mutp53 (U251MG and T98G) and wtp53 (U87MG) cells after infection with Ad.wtp53 (Figure 4 ). In the case of U251MG cells, levels of p53 protein decrease during the course of infection, and a lower molecular weight protein is detected, which may represent a p53 degradation product. These results support the conclusion that differential growth suppression in PHFA-Im and U87MG cells vs U251MG and T98G cells following infection with Ad.wtp53 is not a consequence of failure to infect these cells or express the p53 transgene.
Ad.mda-7 induces apoptosis selectively in malignant gliomas
Infection of diverse human cancers, but not normal cells, with Ad.mda-7 results in a loss in viability by induction of programmed cell death (apoptosis) (Su et al., 1998 Figure 2 Temporal effects on mda-7 mRNA expression in normal and immortal human fetal astrocytes and malignant gliomas after infection with Ad.mda-7. The indicated cell type was infected with 100 PFU/cell of Ad.mda-7, and total RNA was isolated at the times indicated and analyzed by Northern blotting. An equal amount of 10 mg of each RNA sample was analyzed by Northern blotting. Blots were probed with a random-primed [ 32 P]-labeled mda-7 cDNA, and the blots were stripped and then reprobed with a random-primed [ Peak shift is calculated as a ratio (P CAR ÀP control )/P control , where P is the median of the fluorescent peak of the FACS histogram. D value represents the differences between the two curves (Kolmogorov-Smirnov test); higher numbers reflect enhanced binding and increased CAR availability. , 2002 Mhashilkar et al., 2001; Lebedeva et al., 2002; Pataer et al., 2002; Sarkar et al., 2002b) . Annexin V staining and FACS analysis demonstrated that infection with 100 PFU/cell of Ad.mda-7 increased the percentage of early apoptotic cells in U87MG, U251MG and T98G cells, and elevated the levels of late apoptotic and necrotic cells, most markedly in T98G cells ( Figure 5 ). In contrast, no significant change in the percentage of apoptotic cells was evident in gliomas infected with 100 PFU/cell of Ad.vec (adenovirus lacking the transgene insert). Infection of PHFA-Im with 100 PFU/cell of Ad.mda-7 or Ad.vec also did not significantly change the percentage of early or late apoptotic (or necrotic) cells. In the case of Ad.wtp53, both early and late apoptotic (or necrotic) U251MG and T98G cells were increased after infection with 100 PFU/ cell, but apoptosis was not induced in PHFA-Im or wtp53 U87MG cells ( Figure 5 ). Cell cycle analysis after infection with Ad.mda-7 or Ad.wtp53 provided additional support for induction of apoptosis in specific gliomas by these viruses ( Figure 6 ). In the case of Ad.mda-7, a temporal increase in the proportion of cells with a sub G 0 /G 1 (A 0 ) DNA content was evident in U87MG, U251MG and T98G cells ( Figure 6 ). At day 3 after infection with 100 PFU/cell of Ad.mda-7, B59, B46 and B31% of U251MG, U87MG and T98G cells, respectively, contained an A 0 DNA content. In the case of Ad.wtp53, an increase in A 0 DNA content was apparent in mutp53 U251MG (B93%; at day 3) and T98G (B27%; at day 3) cells, but not in wtp53 U87MG cells ( Figure 6 ). In contrast, except for a small increase in A 0 DNA content 24 h after Ad.mda-7 or Ad.wtp53 infection, only control baseline A 0 DNA content was evident in PHFA-Im 48 or 72 hpi with the different viruses. Similarly, analysis of DNA fragmentation using the TUNEL reaction and FACS analysis indicated induction of apoptosis by Ad.mda-7 in glioma cells, U87MG (B44%; day 2), U251MG (B62%; day 2) and T98G (B69%; day 2), but not in PHFA-Im (B1%; day 2). Figure 4 Production of wtp53 protein in PHFA-Im and malignant gliomas following infection with Ad.wtp53. Cells were untreated (control) or infected with 100 PFU/cell of Ad.vec or Ad.wtp53 and protein samples were collected in RIPA buffer at different time points. Samples (30 mg of total protein) were run on 12% SDS-PAGE, transferred to Immobilon P PVDF membranes and stained with anti-p53 monoclonal antibody as described in the Materials and methods section Figure 3 Determination of intracellular and secreted MDA-7 protein in immortal human fetal astrocytes and malignant gliomas after infection with Ad.mda-7. Normal immortalized primary human fetal astrocytes (PHFA-Im) and malignant gliomas (U87MG, U251MG and T98G) were untreated (control) or infected with 100 PFU/cell of Ad.vec and Ad.mda-7, and 24 and 48 hpi supernatants were collected and 24, 48 and 72 hpi cell lysates were collected and levels of MDA-7 protein were determined by Western blotting as described in the Materials and methods section. A total of 25 ml of supernatant and 50 mg of cell lysates were used for Western blotting assays. Arrows on the left indicate secreted MDA-7 protein and brackets and arrows on the right indicate multiple-sized MDA-7 proteins in cell lysates
Previous studies reveal that Ad.mda-7 infection can induce an increase in the percentage of specific cancer cell types in the G 2 /M phase of the cell cycle (Saeki et al., 2000; Mhashilkar et al., 2001; Lebedeva et al., 2002) . Infection of U87MG, U251MG and T98G gliomas with Ad.mda-7 increased the percentage of cells in the G 2 /M phase of the cell cycle by 24 hpi, with no further increase after 48 or 72 hpi ( Figure 7 ). The magnitude of this cell cycle effect was greatest in U251MG cells. In contrast, only a marginal increase (p2%) in cells in the G 2 /M phase of the cell cycle was apparent after Ad.mda-7 infection of PHFA-Im ( Figure 7 ). In the case of Ad.wtp53, an increase in cells in the G 2 /M phase of the cell cycle was apparent in both U251MG and T98G cells, but not in U87MG cells or PHFA-Im ( Figure 7 ). These results provide additional support for a selective effect of Ad.mda-7 on cell cycle in human gliomas, which is independent of p53 genotype. In contrast, Ad.wtp53 induces cell cycle alterations only in human gliomas that have a mutp53 genotype.
Ad.mda-7 alters levels of proapoptotic and antiapoptotic proteins selectively in malignant gliomas
Infection of diverse cancer cells with Ad.mda-7 results in an elevation in the levels of BAX protein and alters the ratio of BAX to BCL-2 proteins (Su et al., 1998 Madireddi et al., 2000; Mhashilkar et al., 2001; Lebedeva et al., 2002) . Studies in human melanoma also indicate changes in the levels of additional proapoptotic proteins, such as BAK, and antiapoptotic proteins, such as BCL-XL, in specific melanomas, but not in normal melanocytes, following infection with Ad.mda-7 (Lebedeva et al., 2002) . Based on these considerations, the temporal effect of infection with 100 PFU/cell of Ad.mda-7, Ad.wtp53 or Ad.vec on the levels of antiapoptotic proteins, BCL-2 and BCL-XL, and proapoptotic proteins, BAX and BAK, was determined by Western blotting (Figure 8 and Table 2 ). In the case of PHFA-Im, no consistent or significant changes were evident in the different apoptosis-associated proteins after 24, 48 or 72 hpi with any of the viruses. In U87MG cells, the levels of BCL-2 and BCL-XL proteins were decreased by 48 h following Ad.mda-7 infection, whereas this effect was not apparent following Ad.wtp53 infection ( Figure 8 and Table 2 ). In these cells, no significant changes were evident in the levels of BAX or BAK following infection with either virus. In mutp53 U251MG cells, a decrease in BCL-2 and increases in both BAX and BAK were apparent after infection with Ad.mda-7 or Ad.wtp53 ( Figure 8 and Table 2 ). In T98G cells, an B1.5 to B1.9-fold decrease in BCL-2 and BCL-XL proteins and an B1.4 to B1.7-fold increase in BAX and BAK proteins occurred after infection with Ad.mda-7 or Ad.wtp53. These results provide additional support for the hypothesis that decreases in the levels of antiapoptotic (BCL-2/BCL-XL) vs proapoptotic (BAX/ BAK) proteins resulting from infection with Ad.mda-7 may be primary mediators of induction of apoptosis in specific cancer cells. In PHFA-Im, the minor changes induced in these protein subtypes following Ad.mda-7 would be anticipated to nullify each other, thereby not affecting cell survival. Similarly, in the case of U87MG cells, infection with Ad.wtp53 did not alter these critical apoptosis-associated proteins and programmed cell death was not induced.
Ad.mda-7 induces GADD gene expression in malignant gliomas
Previous studies indicate that Ad.mda-7 executes its apoptosis-inducing effect by inducing GADD inducible genes in melanoma cell lines (Sarkar et al., 2002b) . In the present study, we determined whether the GADD family of genes was also upregulated in malignant gliomas following Ad.mda-7 infection. Since the GADD family of genes is also modulated by p53, the effect of Ad.wtp53 infection on GADD gene expression in PHFA-Im and in wtp53 and mutp53 malignant gliomas was also investigated. PHFA-Im, wtp53 U87MG cells and mutp53 U251MG cells were infected with 100 PFU/ cell of Ad.vec, Ad.mda-7 or Ad.wtp53, and the expression pattern of the GADD family of mRNAs was examined by Northern blot analysis 1-3 days postinfection. As shown in Figure 9 , Ad.mda-7 infection, but not Ad.vec infection, induced GADD153, GADD45a and GADD34 mRNAs in a time-dependent manner in both U87MG and U251MG cells, which were susceptible to the killing effect of Ad.mda-7 (Figures 5-7) . In both cases, the induction of GADD153 was significantly higher than that of the other GADD genes. However, Ad.mda-7 infection did not induce these genes in PHFAIm, which are resistant to the apoptosis-inducing effects of Ad.mda-7 (Figures 5-7 ). Ad.wtp53 infection induced the GADD family of genes only in U251MG cells, which are killed by Ad.wtp53, but not in PHFA-Im or U87MG cells, which are not killed by Ad.wtp53. These differential expression patterns of the GADD family of genes by Ad.mda-7 and Ad.wtp53 provide further support for Ad.mda-7 as a more suitable therapeutic vector than Ad.wtp53 in the context of gliomas, irrespective of their p53 status.
Ad.mda-7 infection and GST-MDA-7 protein sensitizes malignant glioma cells to radiation-induced growth suppression and induction of apoptosis Mda-7 expression results in the accumulation of specific gliomas in the G 2 /M phase of the cell cycle, and since the G 2 /M phase is known to be the most radiosensitive portion of the cycle, it seemed logical to next determine whether there was any growth-suppressive interaction between exposure of cells to ionizing radiation and expression of mda-7. U87MG and U251MG cells were plated and 24 h later infected with Ad.mda-7 or Ad.vec at an m.o.i. of B50 PFU/cell. Cells were cultured for an additional 24 h prior to irradiation. Cultures were then irradiated (0-8 Gy) and growth was determined 4 days later (5 days after infection) using MTT assays. Parallel experiments examined the amount of apoptosis 4 days after exposure. Expression of mda-7 or irradiation of U87MG and U251MG glioma cells reduced their growth potential. However, the combination of mda-7 and ionizing radiation caused a statistically significant additional decrease in the growth potential of gliomas (Figure 10a ). In agreement with data in Figures 5 and 6 , mda-7 increased the numbers of apoptotic cells, as judged by Wright Giemsa staining for apoptotic cell morphology, which was significantly enhanced following radiation exposure (Figure 10b ). These data suggest that a part of the mechanism by which radiation enhances the antiproliferative effects of mda-7 is by increasing apoptosis.
Because MDA-7 is a secreted protein, now renamed IL-24 (Kotenko, 2002; Pestka et al., 2003; Sarkar et al., 2002a; Sauane et al., 2003) , we performed additional studies, initially to determine whether MDA-7 protein could suppress tumor cell growth, and subsequently to assess the impact of purified MDA-7 on cellular radiosensitivity. Initial studies demonstrated that the culture media of primary rat hepatocytes infected with Ad.mda-7, but not control virus, could suppress the growth of prostate carcinoma cells (Dent, Su, Gopalkrishnan and Fisher, unpublished observations). We then developed a bacterial expression system with mda-7 fused to glutathione-S-transferase to prepare larger quantities of pure MDA-7 protein for further studies (GST-MDA-7). To determine whether purified MDA-7 protein altered cell growth and survival, gliomas were treated with either vehicle (GST) or MDA-7 (GST-MDA-7) (0.25 mg/ml final concentration in media), followed 24 h later by exposure to ionizing radiation. Cell growth was determined 4 days after irradiation using MTT assays.
Treatment with GST-MDA-7 protein or irradiation of U87MG and U251MG gliomas reduced their growth potential. However, the combination of GST-MDA-7 and ionizing radiation caused a statistically significant additional decrease in growth potential of the gliomas (Figure 11 ). GST-MDA-7 also potentiated Figure 7 Cell cycle changes in malignant gliomas following infection with Ad.mda-7 and Ad.wtp53. Cells were untreated (control) or infected with 100 PFU/cell of Ad.vec, Ad.mda-7 or Ad.wtp53, harvested at 24, 48 and 72 hpi, fixed and stained with PI as described in the Materials and methods section. Viable, nonapoptotic cells were gated using CellQuest software, and cell cycle phase distribution of the cells was determined for each cell type. The percentage of cells in G 2 /M phase after Ad.vec, Ad.mda-7 (Upper Panel) or Ad.wtp53 (Lower Panel) infection was determined radiation-induced apoptosis in gliomas, which was qualitatively similar to that resulting from Ad.mda-7 (Figure 10b ) (data not shown). Collectively, these data demonstrate that mda-7 can enhance the antiproliferative and cytotoxic actions of ionizing radiation.
Ad.mda-7 plus radiation results in enhanced induction of the GADD family of genes in malignant glioma cells UV and ionizing radiation are known to cause induction of the GADD family genes, which can play a role in apoptotic processes (Hollander et al., 1997; Amundson et al., 1998; Carrier et al., 1998) . Since Ad.mda-7 infection and GST-MDA-7 facilitated the killing effect of ionizing radiation in malignant gliomas (Figures 10  and 11 ), we determined whether the expression pattern of the GADD family of genes was modulated by the combined treatment of ionizing radiation and Ad.mda-7. As shown in Figure 12 , infection of U251MG and U87MG cells with Ad.mda-7 at an m.o.i. of B50 PFU/ cell, or exposure of cells to ionizing radiation (6 Gy), induced GADD153 expression from day 2 of treatment onward. However, combined treatment of cells with both radiation and mda-7 further augmented the Figure 8 Determination of BCL-2, BCL-XL, BAX, BAK and EF-1a protein levels in normal immortal fetal astrocytes and malignant gliomas following infection with Ad.mda-7 or Ad.wtp53. Cells were untreated (control) or infected with 100 PFU/cell of Ad.vec, Ad.mda-7 or Ad.wtp53 and protein lysates were prepared at the specified time points. Samples of 50 mg of total protein were run on 12% SDS-PAGE, transferred to a PVDF membrane and stained with different antibodies as described in The Materials and methods section. Bcl-family protein expression, as determined by Western blot analysis, was quantitatively analyzed via laser-scanning densitometry using NIH Image Version 1.61 software induction of GADD153, thus providing a possible mechanism underlying the cooperative effect of Ad.-mda-7 and ionizing radiation in killing malignant gliomas.
Discussion
Malignant gliomas represent the most prevalent primary brain tumors in adults (Levin et al., 1997) . Considering the poor prognosis for patients with malignant gliomas, in spite of surgical intervention, radiation therapy and chemotherapy, alternative treatment modalities are urgently needed to stem the severity and aggressiveness of these cancers (Levin et al., 1997; Alexander and Loeffler, 1998 ). An approach that offers potential for achieving this outcome is localized gene therapy because these cancers often recur locally and only rarely metastasize to other organs (Levin et al., 1997) . However, to be successful in achieving this end point, it is necessary to deliver an appropriate gene that can specifically target cancer cells, irrespective of their genetic defect(s), to undergo cell death without eliciting any harmful effects on normal astrocytes and neuronal cells. Since low-grade astrocytoma, anaplastic astrocytoma and glioblastoma multiforme have multiple defects, including genetic changes that appear unique to each disease state (Alemany et al., 1999) , determining the appropriate gene to use for therapeutic purposes in brain tumors can be problematic. Subtraction hybridization between terminally differentiated and untreated control human melanoma cells permitted the cloning of mda-7 (IL-24), a cancer specific apoptosis-inducing cytokine gene (Jiang et al., 1995) . Mda-7 (IL-24) embodies unique properties, including tumor-restricted activity, making it amenable for therapeutic applications in diverse cancers (Su et al., 1998; Madireddi et al., 2000; Chada et al., 2001) . Ad.mda-7 (IL-24) can preferentially induce growth suppression and apoptosis in a wide spectrum of cancer cell types, without inducing similar alterations in growth or survival of normal cells (Su et al., 1998 Madireddi et al., 2000; Saeki et al., 2000 Saeki et al., , 2002 Huang et al., 2001; Mhashilkar et al., 2001; Lebedeva et al., 2002; Pataer et al., 2002; Sarkar et al., 2002a, b; Sauane et al., 2003) . These significant aspects of mda-7 culminated in a recent Phase I Clinical Trial confirming safety and potent antitumor (apoptotic) activity following intratumoral injection . In the present study, we compared and contrasted the effects of administering mda-7/IL-24 vs wtp53 by means of replication-incompetent adenoviruses on the growth and survival of normal and immortal PHFA and malignant gliomas with mutp53 or wtp53 genotypes. These analyses document that mda-7/IL-24 can induce apoptosis in a p53-independent manner in malignant gliomas, whereas administering wtp53 induces apoptosis selectively in mutp53 malignant gliomas. In addition, Ad.mda-7 or purified GST-MDA-7 protein can sensitize both mutp53 and wtp53 malignant gliomas to growth suppression and apoptosis. These results argue that Ad.mda-7 could prove beneficial for the therapy of Figure 9 Induction of GADD family genes following infection with Ad.mda-7 and Ad.wtp53 in malignant gliomas. U87MG, PHFA-Im and U251MG cells were infected with either Ad.vec, Ad.mda-7 or Ad.wtp53 at an m.o.i. of 100 PFU/cell for 3 days. Total RNA was extracted and the expression profiles of GADD153, GADD45a, GADD34 and GAPDH mRNAs were determined by Northern blot analysis malignant gliomas and, in principle, should display a wider spectrum of antiglioma activity than Ad.wtp53. Mda-7 encodes a protein with a predicted size of 23.8 kDa with a 49-amino acid N-terminal hydrophobic signal peptide that permits cleavage and secretion (Jiang et al., 1995; Huang et al., 2001; Mhashilkar et al., 2001; Lebedeva et al., 2002) . Structural analysis indicates that MDA-7 is a member of the four-helix bundle family of cytokine molecules with greatest homology to the IL-10 subfamily, which now includes IL-19, IL-20, IL-22 
0 Gy 6 Gy 6 Gy 0 Gy U251MG U87MG * # * * * # Figure 11 Purified GST-MDA-7 protein sensitizes malignant glioma cells to radiation-induced growth suppression. U87MG and U251MG cells were plated as described in the Materials and methods section, and 24 h later were incubated with GST-MDA-7 or control (GST) at a final concentration of 0.25 mg/ml. Cells were cultured for an additional 30 min prior to irradiation. Cells were then irradiated (6 Gy) and the growth of cells determined 4 days later (5 days after infection) using MTT assays. Figure 12 The combination of Ad.mda-7 and irradiation synergistically induce GADD153 expression in mutp53 and wtp53 gliomas. U251MG (mutp53) and U87G (wtp53) gliomas were infected with Ad.mda-7 or Ad.vec and irradiated as described in Figure 10 . The cells were harvested day 1 to day 3 postirradiation, total RNA was extracted and the expression of GADD153 and GAPDH mRNAs was analyzed by Northern blotting analysis as described in the Materials and methods section (IL-TIF) and AK-155 (Chaiken and Williams, 1996; Gallagher et al., 2000; Xie et al., 2000; Zhang et al., 2000; Huang et al., 2001; Kotenko et al., 2001; Kotenko, 2002; Pestka et al., 2003) . Although IL-10 and mda-7 share o20% sequence identity, mda-7 has an IL-10 signature sequence indicating its relationship to the IL-10 subfamily. Based on these structural considerations, its secretory properties and presumed cytokine-like properties, mda-7 has been renamed IL-24 by the HUGO nomenclature system. When administered at low concentration, mda-7 may function predominantly as a cytokine (Caudell et al., 2002) , whereas when administered at supra-physiological levels (by Ad infection), mda-7 displays cancer-cell-specific growth inhibitory and apoptosis-inducing properties (Su et al., 1998 Saeki et al., 2000 Saeki et al., , 2002 Madireddi et al., 2000; Huang et al., 2001; Mhashilkar et al., 2001; Lebedeva et al., 2002; Pataer et al., 2002; Sarkar et al., 2002a, b; Sauane et al., 2003) .
As observed with several normal cell types, including endothelial, bronchial, mammary and prostate epithelial, skin and lung fibroblasts and melanocytes (Jiang et al., 1996; Su et al., 1998; Madireddi et al., 2000; Saeki et al., 2000 Saeki et al., , 2002 Mhashilkar et al., 2001; Lebedeva et al., 2002; Sarkar et al., 2002b) , infection of PHFA with Ad.mda-7 only modestly affected growth without decreasing cell survival (Figures 1, 5 and 6 ). In contrast, growth was dramatically inhibited in both mutp53 and wtp53 malignant gliomas by Ad.mda-7, whereas Ad.wtp53 preferentially targeted mutp53 gliomas for growth suppression (Figure 1 ). The ability of Ad.mda-7 to inhibit malignant glioma growth while sparing PHFA was not a consequence of resistance of normal astrocytes to Ad infection or their failure to produce mda-7 transgene mRNA and/or synthesize and secrete MDA-7 protein (Figures 2 and 3 ). Experiments were performed to address the potential mechanism underlying this differential apoptosis-inducing effect of mda-7/IL-24 toward malignant gliomas vs normal astrocytes. It is well established in multiple model systems that the relative levels of gene products protecting cells from apoptosis (antiapoptotic proteins, such as BCL-2 and BCL-XL) vs the levels of gene products promoting apoptosis (proapoptotic proteins, such as BAX and BAK) are important arbiters of cell survival or death (Green and Reed, 1998) . In this context, several previous studies demonstrate that changes in the amount and ratio of pro apoptotic to anti apoptotic proteins following Ad.mda-7 infection may play a prominent role in mediating the differential sensitivity of cancer cells vs normal cells to mda-7/IL-24 (Su et al., 1998 Madireddi et al., 2000; Saeki et al., 2000; Mhashilkar et al., 2001; Lebedeva et al., 2002) . This also appears to be the case in malignant gliomas following infection with Ad.mda-7. Infection of PHFA-Im cells with either Ad.mda-7 or Ad.wtp53 did not significantly tip the balance between levels of pro-apoptotic (BAX and BAK) to antiapoptotic (BCL-2 and BCL-XL) proteins ( Figure 8 , Table 2 ). In contrast, increases in the ratio of proapoptotic to antiapoptotic proteins were evident in U87MG, U251MG and T98G cells infected with Ad.mda-7, and in U251MG and T98G cells infected with Ad.wtp53. These data support the hypothesis that these apoptosis-inducing cancer growth suppressor genes may induce their effects by altering the ratio of proapoptotic to antiapoptotic proteins specifically in sensitive cancer cells.
Recent studies have begun to address the signaling pathways involved in Ad.mda-7 induction of apoptosis in cancer cells (Pataer et al., 2002; Sarkar et al., 2002a, b) . Inhibition of mitogen-activated protein kinase (MAPK) pathways, specifically p38 MAPK by its specific inhibitor SB203580, diminishes the apoptosis-inducing effect of Ad.mda-7 (Sarkar et al., 2002b) . In human melanoma cells, Ad.mda-7 infection initiates phosphorylation of p38 MAPK and its downstream target heat shock protein 27 (HSP27), whereas these biochemical changes were not apparent in Ad.mda-7 apoptosis-resistant immortal normal human melanocytes (Sarkar et al., 2002b) . Apoptosis induction triggered by p38 MAPK activation is mediated by the induction of the GADDinducible family of genes (Brenner et al., 1997; Kultz et al., 1998; Oh-Hashi et al., 2001) . This gene family consists of GADD34, GADD45a, GADD45b, GADD45g and GADD153, which encode highly acidic nuclear proteins with similar and unusual charge characteristics (Zhan et al., 1994; Takekawa and Saito, 1998) . Overexpression of each GADD gene causes growth inhibition and/or apoptosis, and combined overexpression of the GADD genes leads to synergistic or cooperative antiproliferative effects (Zhan et al., 1994) . Infection of metastatic human melanoma cells with Ad.mda-7 resulted in the marked induction of GADD153, GADD45a and GADD34, whereas this induction was not apparent in immortal normal human melanocytes (Sarkar et al., 2002b) . Moreover, antisense inhibition of the different members of the GADD gene family partially blocked induction of apoptosis by Ad.mda-7, with the greatest inhibition apparent when the various antisense constructs were used in combination (Sarkar et al., 2002b) . Ad.mda-7 induced expression of GADD34, GADD45a and GADD153 in U87MG and U251MG, but not in normal immortal astrocytes (PHFA-Im) (Figure 9 ). In contrast, Ad.wtp53 only induced these GADD family gene members in U251MG cells, which are killed by Ad.wtp53, but not in PHFA-Im or U87MG cells, which are resistant to killing by wtp53. Infection of lung cancer cells with Ad.mda-7 resulted in phosphorylation of PKR and also its downstream targets eIF-2a, Tyk2, Stat1, Stat3 and p38 MAPK (Pataer et al., 2002) . Phosphorylation of eIF-2a activates the transcription factor ATF-4, which activates GADD153 (Fawcett et al., 1999; Harding et al., 2000) . In this context, there is a significant level of cross talk between the PKR and p38 MAPK signal transduction pathways. Further studies are required to determine if PKR activation occurs following Ad.mda-7 infection of malignant gliomas. Additionally, the upstream molecules regulating p38 MAPK and PKR pathways need to be identified to delineate the signal transduction pathways by which Admda-7 induces apoptosis selectively in diverse human cancers.
The cytokine properties of mda-7 have been currently established (Caudell et al., 2002) , and IL-20/IL-22 receptor binding described recently (Dumoutier et al., 2001; Wang et al., 2001) could account for much of its observed cytokine activity. It is presently unclear if the cytokine nature overlaps and/or contributes to its anticancer cell activity, although it is apparent and probably expected that supra-physiological levels of expression have additional effects on cells (Sarkar et al., 2002a, b; Sauane et al., 2003) . In this context, it is clear that treatment of cells with bacterially expressed and purified GST-MDA-7 protein is able to reproduce the cancer cell specificity seen with Ad.mda-7 (Figure 11 ). Since the purified protein is applied externally to cells, one might consider receptor-mediated activity as a primary mode of cancer cell killing. An open question at the present time, for activity seen at supraphysiological levels, is whether receptor specificity is maintained or whether additional, low-affinity receptors come into play under certain conditions. It is likely that triggering of additional pathways in a cancer cell-specific manner with additional synergy on exposure to radiation occurs.
Expression of wtp53 has previously been shown to radiosensitize glioma cells, regardless of p53 functional status of the transduced cells (Shono et al., 2002) . Perhaps more surprisingly, transduction of mutp53 into gliomas was also capable of inducing a radiosensitive phenotype (Broaddus et al., 1999) . However, as noted previously in this manuscript, a recombinant adenovirus expressing an intracellular protein, such as p53, will probably only radiosensitize tumor cells that are infected with the virus, which reduces the likelihood that this gene therapy approach can be successfully translated into the clinic.
In contrast to studies with p53, the present findings and unpublished studies with Ad.mda-7 and GST-MDA-7 demonstrate that mda-7 protein expressed in rat hepatocytes and secreted into the growth media could inhibit the proliferative potential of DU-145 prostate carcinoma cells and, furthermore, that viral expression of mda-7 in human gliomas or treatment of human gliomas with purified GST-MDA-7 protein reduced cell growth, enhanced radiosensitivity and increased apoptosis. Of note, while human and rodent gliomas are radiosensitized by Ad.mda-7, infection of primary rodent astrocytes with Ad.mda-7 did not suppress growth and did not further enhance the growth suppression observed following irradiation (Yacoub, Fisher and Dent, unpublished observations) . Collectively, these findings argue that mda-7 expressed in one cell can have an antiproliferative and radiosensitizing bystander effect on surrounding tumor cells. These findings are in general agreement with our previously published data showing that mda-7 is a secreted protein (Lebedeva et al., 2002) and that low levels of mda-7 expression in vivo can suppress tumor formation .
The present studies convincingly document that mda-7 selectively induces growth suppression and apoptosis in malignant gliomas, in a p53 independent manner, whereas wtp53 also spares normal astrocytes, but growth suppression and apoptosis is restricted to mutp53 gliomas. Induction of apoptosis by mda-7 correlates with changes in the ratio of proapoptotic to antiapoptotic proteins and induction of the GADD family of genes. Moreover, infection of wtp53 or mutp53 gliomas with Ad.mda-7 or treatment with purified GST-MDA-7 protein sensitizes these tumor cells to the growth-inhibitory and antisurvival effects of ionizing radiation. Considering the tumor selectivity and apparent safety of Ad.mda-7 in patients and the heterogeneous p53 nature of evolving gliomas, these findings provide support for future translational applications of mda-7, alone and in combination with radiation, for the therapy of malignant gliomas.
Materials and methods

Cell lines and culture conditions
Fetal astrocytes were isolated from second trimester (gestational age 16-19 weeks) human fetal brains obtained from elective abortions in full compliance with NIH guidelines, as previously described (Bencheikh et al., 1999; Canki et al., 2001; Su et al., 2002) . Highly homogeneous preparations of primary normal human fetal astrocytes, PHFA, were obtained using high-density culture conditions in the absence of growth factors in F12 Dulbecco's modified Eagle medium (DMEM) (GIBCO-BRL, Gaithersburg, MD, USA) containing 10% fetal bovine serum (FBS), penicillin, streptomycin and gentamycin. Cells were maintained in this medium at 2-5 Â 10 4 cells/cm 2 and subcultured weekly up to 6 times. Cultures were regularly monitored for expression of the astrocytic marker glial fibrillary acidic protein (GFAP) and either HAM56 or CD68 to identify cells of monocyte/ macrophage lineage. Only cultures that contained X99% GFAP positive astrocytes and rare or no detectable HAM56 or CD68 positive cells were used in experiments (Canki et al., 2001; Su et al., 2002) . A putative immortalized clone of PHFA, PHFA-Im, was obtained by infection with a retrovirus (pBabehygro-hTERT) expressing the human telomerase (hTERT) gene (Hahn et al., 1999) . Pseudotyped retrovirus was obtained by transfection of 293GPG cells with pBabe-hygro-hTERT plasmid as described (Ory et al., 1996) , which were used for infection of PHFA cells and selection of clones with hygromycin at 200 mg/ml for 2 weeks, followed by isolation of individual colonies using cloning cylinders. These were expanded and frozen at low passage. Cell lines were tested for expression of hTERT by Northern blot analyses and survival of colonies over several passages (primary astrocytes do not survive extended serial passage >B10). PHFA-Im cells have now been cultured for >50 passages, whereas proliferation of PHFA usually did not occur past B7 passages. The wtp53 human glioma cell line U87MG and the mutp53 human glioma cell lines U251MG, U373MG and T98G were obtained from the American Type Culture Collection. Cell lines were grown in DMEM supplemented with 10% fetal bovine serum (DMEM-10) at 37 o C in a 95% air 5% CO 2 humidified incubator.
Virus construction, plaque assays and virus infection protocol
The recombinant replication-defective Ad.mda-7 virus was created in two steps as described previously (Su et al., 1998) . Briefly, the coding region of the mda-7 gene was cloned into a modified Ad expression vector pAd.CMV (Falck-Pedersen et al., 1994) . This vector contains, in order, the first 355 bp from the left end of the Ad genome, the cytomegalovirus immediate early promoter, DNA encoding splice donor and acceptor sites, the coding region of the mda-7 cDNA, DNA encoding a polyA signal sequence from the b globin gene, and B3 kbp of adenovirus sequence extending from within the E1B coding region. This arrangement allows high-level expression of the cloned sequence by the cytomegalovirus immediate early gene promoter, and appropriate RNA processing (FalckPedersen et al., 1994) . The recombinant virus was created in vivo in 293 cells (Graham et al., 1977) by homologous recombination between mda-7-containing vector and plasmid JM17, which contains the whole of the Ad genome cloned into a modified version of pBR322 (McGrory et al., 1988) . JM17 gives rise to Ad genomes in vivo, but they are too large to package. This constraint is relieved by recombination with the vector to create a packageable genome (McGrory et al., 1988) , containing the mda-7 gene. The recombinant virus is replication defective in human cells except 293 cells, which express adenovirus E1A and E1B. Following transfection of the two plasmids, infectious virus was recovered, the genomes were analyzed to confirm the recombinant structure, and then virus was plaque purified, all by standard procedures (Volkert and Young, 1983) . Stock virus preparations were diluted in DMEM containing 1% fetal bovine serum and inoculated onto cell monolayers at the indicated m.o.i. After 2 h virus adsorption at 371C with rotation every 15 min, the virus inoculum was removed and DMEM-10 was added to the infected monolayer cultures and cells were incubated at 371C for the indicated times.
RNA isolation and Northern blotting assays
For determining temporal effects of mda-7 mRNA expression following Ad.mda-7 infection, total cellular RNA was isolated by the guanidinium/phenol extraction method and Northern blotting was performed as described (Su et al., 1997) . A total of 15 mg of RNA was denatured and electrophoresed in 1.2% agarose gels with 3% formaldehyde, transferred to nylon membranes and hybridized sequentially with 32 P-labeled mda-7 cDNA probe, the blot was stripped and reprobed with a 32 Plabeled gapdh probe as described previously (Su et al., 1997 (Su et al., , 1999 . For analysis of GADD family gene expression, total RNA was extracted from the cells by a Qiagen RNeasy mini kit according to the manufacturer's protocol. In all, 10 mg of total RNA for each sample was used for Northern blotting as previously described (Su et al., 1997) . Blots were probed with a-32 P[dCTP]-labeled cDNA probes, including full-length human mda-7, GADD153, GADD45a and a 500-bp fragment from human GADD34. Blots were stripped and reprobed with an a-32 P[dCTP]-labeled human GAPDH probe. Following hybridization, the filters were washed and exposed for autoradiography.
Cell cycle analysis
Cells were trypsinized, washed 2 Â with phosphate-buffered saline (PBS) and fixed in 70% ethanol overnight at À201C. Then cells were washed 2 Â with PBS, and aliquots of 1 Â 10 6 cells were resuspended in 1 ml of PBS containing 1 mg/ml of RNase A and 0.5 mg/ml of propidium iodide. After 30 min incubation, cells were analyzed by flow cytometry using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA).
Annexin-V binding assay
Cells were trypsinized and washed once with complete media. The aliquots of the cells (5 Â 10 5 ) were resuspended in complete media (0.5 ml) and stained with fluorescein isothiocyanate (FITC)-labeled Annexin-V (kit from Oncogene Research Products, Boston, MA, USA) according to the manufacturer's instructions. Propidium iodide (PI) was added to the samples after staining with Annexin-V to exclude late apoptotic and necrotic cells. The FACS assay was performed immediately after staining.
Detection of CAR receptors on the cell surface
Cells were harvested by trypsinization, washed 2 Â with PBS and stained with 1:1000 dilution of monoclonal anti-CAR antibody, for 1 h at 371C. After additional washings with PBS (2 Â 5 min), cells were stained in the dark for 1 h at 371C with a 1 : 500 dilution of fluorescein-labeled goat anti-mouse immunoglobulins (BioSource International, Camarillo, CA, USA). After washings with PBS, cells were analyzed by flow cytometry (5 Â 10 5 cells/sample). Unstained cells and cells stained with monoclonal anti-SV40 antibody (Santa Cruz, CA, USA) and with secondary antibody only were used as controls. Two methods were employed for semiquantitation of the results (Lebedeva et al., 2002a) . The shift of the FL1 peak was calculated as the difference in peak channels between the control (cells unstained or stained with nonspecific antibody) and the experimental cells stained with anti-CAR antibody relative to the position of the control cell peak channel. The second method uses the Kolmogorov-Smirnov (K-S) test for overlaid histograms (Young, 1977) . The calculation computes the summation of the overlaid curves and determines the greatest difference between the summation curves (K-S statistics). The D value indicates the greatest difference between the two curves.
TUNEL assay
After the different treatment protocols, cells were trypsinized, washed twice with PBS/1%BSA and resuspended in PBS/ 1%BSA. Suspended cells (1 Â 10 6 ) were fixed with an equal amount of a freshly prepared paraformaldehyde solution (4% in PBS, pH 7.4). After 30 min incubation at room temperature, cells were washed with PBS and resuspended in permeabilization solution (0.1% Triton s X-100 in 0.1% sodium citrate) for 2 min on ice. After another wash with PBS, cells were labeled using a fluorescein cell death detection kit (Boehringer Mannheim) according to the manufacturer's instructions. After the labeling, cells were analysed by flow cytometry using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA).
Expression, purification and analysis of GST-MDA-7 protein Standard cloning procedures were used to generate a bacterial expression vector comprising in-frame fusion of the mda-7 ORF 3 0 to the GST ORF in GST-4T2 vector (Amersham Pharmacia), using BamHI and NotI sites introduced into mda-7 by PCR. Expression of protein was performed by inoculating an overnight culture at 1 : 100 dilution followed by incubation at 251C until an OD 600 of 0.4-0.6 was reached followed by induction with 0.1 mm IPTG for 2 h. Cells were harvested by centrifugation and sonicated in PBS followed by centrifugation to obtain soluble protein. The lysate was bound to a glutathione-agarose column (Amersham Pharmacia) at 41C overnight followed by washing with 50 volumes PBS and 10 volumes PBS with 500 mm NaCl. Elution of bound protein was performed by passing 20 mm-reduced glutathione through the column and collecting 1 ml fractions. Fractions were analyzed by gel electrophoresis, and positive samples were dialyzed against 1000 volumes of PBS for 4 h with one change followed by 500 volumes of DMEM for 4 h. Protein concentration was estimated by Bradford assays as well as gel electrophoresis in conjunction with Coomassie blue staining. Samples were tested for activity using GST protein as control. Each batch of protein had a certain effective working concentration (cell killing) ranging from 2 to 10 mg/ml.
Western blot analysis
Western blot assays were performed as previously described (Lebedeva et al., 2002) . Cells were washed 2 Â with cold PBS and lysed on ice for 30 min in 100 ml of cold RIPA buffer (50 mm Tris-HCl (pH 8.0), 150 mm NaCl, 0.1% SDS, 1% NP40, and 0.5% sodium deoxycholate) with freshly added 0.1 mg/ml phenylmethylsulfonyl fluoride, 1 mm sodium orthovanadate, and 1 mg/ml aprotinin. Cell debris were removed by centrifugation at 14 000 g for 10 min at 41C. Protein concentrations were determined using the Bio-Rad protein assay system (Bio-Rad Laboratories, Richmond, CA, USA). Aliquots of cell extracts containing 20-50 mg of total protein were resolved in 12% SDS-PAGE and transferred to Immobilon-P PVDF membranes (Millipore Corp., Bedford, MA, USA). Filters were blocked for 1 h at room temperature in Blotto A (5% nonfat milk powder in TBS-T: 10 mm Tris-HCl (pH 8.0), 150 mm NaCl, 0.05% Tween 20), and then incubated for 1 h at room temperature in Blotto A containing a 1:1000 dilution of rabbit anti-MDA-7, anti-BCL-2, anti-BCL-XL, anti-BAX or anti-BAK polyclonal antibodies. After washing in TBS-T buffer (3 Â 5 min, RT), filters were incubated for 1 h at room temperature in Blotto A containing a 1:10 000 dilution of peroxidase-conjugated anti-rabbit secondary antibody (Amersham, Arlington Heights, IL, USA). After washing in TBS-T, ECL was performed according to the manufacturer's recommendation. Bcl-family proteins expression as determined by Western blot analysis was quantitatively analyzed via laserscanning densitometry using NIH Image Version 1.61 software. All results were normalized to EF-1a protein expression.
Radiosensitization assay
U87MG and U251MG cells were plated at 10 4 cells/well of a 12-well plate (Fisher Scientific) and cultured as described above. Cells were infected at an m.o.i of 50 PFU/cell (based on the initial plating of 10 4 cells) 24 h after plating. This is probably an overestimate of the PFU/cell. Alternatively, cells were treated with either purified GST or GST-MDA-7 (0.25 mg/ml, final concentration) in media. Cells were exposed to radiation or mock irradiated (6 Gy) 24 h after infection or protein treatment, at a dose rate of 2.1 Gy/min using a Picker 60 Co source. Four days after irradiation, cells were processed to determine (a) their growth via MTT assays and (b) their viability by Wright Giemsa staining of fixed cells (Carter et al., 1998; Vrana et al., 1999; Dai et al., 2001) .
Wright Giemsa staining of cells to determine apoptosis
Cells were isolated 96 h after irradiation by trypsinization followed by centrifugation onto glass slides (cytospin). The slides were fixed and stained in Diff-Quik 7 Stain Set (Dade Diagnostics of P.P. Inc., Aguada, PR, USA), according to the manufacturer's instructions, and viewed under a light microscope (Rosato et al., 2001) . Randomly selected fields of fixed cells (B150 cells per field, n ¼ 5 per slide) were counted and the percentage apoptosis determined.
MTT assay to determine cell growth
Cells were grown in 12-well plates and 96 h after irradiation prepared for MTT assays. A 5-mg/ml stock solution of MTT reagent (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; thiazolyl blue) was prepared in DMEM. For assay of mitochondrial dehydrogenase function, the MTT stock solution is diluted 1:10 in fresh media (DMEM+10% fetal calf serum) and 1 ml of this solution is added to each aspirated well of a 12-well plate. Cells are incubated for a further 3 h at 371C. MTT is converted into an insoluble purple formazan by cleavage of the tetrazolium ring by mitochondrial dehydrogenase enzymes. After 3 h, media are aspirated and cells lysed with 1 ml DMSO, releasing the purple product from the cells. Cells are incubated for a further 10 min at 371C with gentle shaking. Absorbance readings at 540 nm are determined using a computer-controlled microplate analyzer. The relationship between cell number and MTT absorbance/mitochondrial enzyme activity was linear over the range of 10 4 -10 6 cells.
